Clinical Trials Logo

Clinical Trial Summary

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum doublet induction chemotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03498521
Study type Interventional
Source Hoffmann-La Roche
Contact Reference Study ID Number: MX39795 www.roche.com/about_roche/roc
Phone 888-662-6728 (U.S. Only)
Email global-roche-genentech-trials@gene.com
Status Recruiting
Phase Phase 2
Start date July 10, 2018
Completion date April 16, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03278600 - Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary Phase 3
Recruiting NCT03053466 - CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Phase 1
Not yet recruiting NCT03752333 - Trial of Pembrolizumab in Cancer of Unknown Primary Phase 2
Recruiting NCT01845337 - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Phase 2